Literature DB >> 11032761

Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats.

A W Stitt1, T Bhaduri, C B McMullen, T A Gardiner, D B Archer.   

Abstract

Advanced glycation end products (AGEs) have been implicated in the progressive vascular dysfunction which occurs during diabetic retinopathy. In the current study we have examined the role of these adducts in blood-retinal barrier (BRB) breakdown and investigated expression of the vasopermeabilizing agent vascular endothelial growth factor (VEGF) in the retina. When normoglycemic rats were injected with AGE-modified albumin daily for up to 10 days there was widespread leakage of FITC-dextran and serum albumin from the retinal vasculature when compared to control animals treated with nonmodified albumin. Ultrastructural examination of the vasculature revealed areas of attenuation of the retinal vascular endothelium and increased vesicular organelles only in the AGE-exposed rats. Quantitative RT-PCR and in situ hybridization demonstrated a significant increase in retinal VEGF mRNA expression (P < 0.05). These results suggest that AGEs can initiate BRB dysfunction in nondiabetic rats and a concomitant increase in retinal VEGF expression. These findings may have implications for the role of AGEs in the pathogenesis of diabetic retinopathy. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032761     DOI: 10.1006/mcbr.2000.0243

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  42 in total

Review 1.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.

Authors:  Ahmed S Ibrahim; Mamdouh M El-Shishtawy; Wenbo Zhang; Ruth B Caldwell; Gregory I Liou
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Basement membrane changes in capillaries of the ageing human retina.

Authors:  Michael B Powner; Andrew Scott; Meidong Zhu; Peter M G Munro; Alexander J E Foss; Gregory S Hageman; Mark C Gillies; Marcus Fruttiger
Journal:  Br J Ophthalmol       Date:  2011-05-23       Impact factor: 4.638

4.  Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.

Authors:  Ashish Thakur; Robert I Scheinman; Vidhya R Rao; Uday B Kompella
Journal:  Microvasc Res       Date:  2011-09-16       Impact factor: 3.514

Review 5.  Caveolins and caveolae in ocular physiology and pathophysiology.

Authors:  Xiaowu Gu; Alaina M Reagan; Mark E McClellan; Michael H Elliott
Journal:  Prog Retin Eye Res       Date:  2016-09-21       Impact factor: 21.198

6.  MicroRNA-409-5p promotes retinal neovascularization in diabetic retinopathy.

Authors:  Ying Wang; Wenwen Lin; Jianghua Ju
Journal:  Cell Cycle       Date:  2020-04-15       Impact factor: 4.534

Review 7.  Too sweet: Problems of protein glycation in the eye.

Authors:  Eloy Bejarano; Allen Taylor
Journal:  Exp Eye Res       Date:  2018-08-24       Impact factor: 3.467

8.  Effect of diabetes on transscleral delivery of celecoxib.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Pharm Res       Date:  2008-11-06       Impact factor: 4.200

9.  Effects of crystallin-β-b2 on stressed RPE in vitro and in vivo.

Authors:  Michael R R Böhm; Harutyun Melkonyan; Patrick Oellers; Solon Thanos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-17       Impact factor: 3.117

10.  Pituitary Adenylate Cyclase Activating Polypeptide, A Potential Therapeutic Agent for Diabetic Retinopathy in Rats: Focus on the Vertical Information Processing Pathway.

Authors:  K Szabadfi; D Reglodi; A Szabo; B Szalontai; A Valasek; Gy Setalo; P Kiss; A Tamas; M Wilhelm; R Gabriel
Journal:  Neurotox Res       Date:  2016-01-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.